This page shows the latest eosinophilic news and features for those working in and with pharma, biotech and healthcare.
Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the European Commission as the first and only targeted medicine for eosinophilic oesophagitis (EoE), the companies announced.
with nasal polyposis, or eosinophilic esophagitis in different age populations.
with eosinophilic oesophagitis (EoE).
Additionally, certain MPNs may become acute myeloid leukaemia. MPNs include chronic myelogenous leukaemia (CML), polycythaemia vera (PV), primary myelofibrosis (MF), essential thrombocythaemia (ET), chronic neutrophilic leukaemia and chronic
The Regulus programme is working to develop a next-generation JAK1 inhibitor for eosinophilic oesophagitis. ... The Regulus programme is focused on developing a next-generation JAK1 inhibitor and Aqilion will start by testing, assessing and developing
There are currently no approved treatments for children with eosinophilic oesophagi under the age of 12. ... Sanofi and Regeneron have announced positive results from a phase 3 trial assessing the investigational use of Dupixent (dupilumab) in children
More from news
Approximately 7 fully matching, plus 54 partially matching documents found.
Having too many eosinophils in certain tissues is an important contributor to a range of conditions including severe eosinophilic asthma (SEA), nasal polyps, eosinophilic oesophagitis and rarer, systemic diseases such as ... Interestingly, Howarth
It also plans to achieve the first FDA therapy approval to treat eosinophilic oesophagitis, a chronic, allergic condition with little current respite.
mepolizumab to treat COPD exacerbations with eosinophilic inflammation. ... You would imagine coronavirus would be one of those threats.”. GSK is trialling its biologic anti IL-5 drug mepolizumab, licensed for severe asthma, in eosinophilic COPD with a
GSK is also anticipating data in hyper-eosinophilic syndrome and nasal polyposis which could lead to commercial approvals in both by the end of 2020. ... Severe eosinophilic asthma (SEA) impacts between 5-10% of the population but they, and other severe
Baxalta aside, it has been a busy year for Shire which in February acquired the company Meritage bringing in a phase III ready oral budesonide solution for eosinophilic oesophagitis [an orphan
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Inhale, Exhale: The struggle of living with Severe Asthma and Severe Eosinophilic Asthma. ... Head of “Living With”, Mariel Metcalfe, discusses the nature of severe asthma and severe eosinophilic asthma, and some key findings from recent studies
Inhale, Exhale: The struggle of living with Severe Asthma and Severe Eosinophilic Asthma.
More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.
Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...